Sakar Healthcare share price, P/E, ROE & financials

On 6 Nov 2026, Sakar Healthcare was priced at ₹975.55, or 70.9× trailing earnings, against an industry P/E of 28.7×, and the shares are 21% below their 52-week high. Its ROCE of 13% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 24% and 34% a year over 3 years. Debt is 0.18× equity. It is a small-cap company with a market cap of ₹2,141 Cr, ranked 56th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 178% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Mar 2026.How we calculate this

past year

Open: ₹1,015.90
Day high: ₹1,018.95
Day low: ₹956.00
Prev. close: ₹1,015.90
Volume: 86.6K

Health check

2 good · 2 fair · 2 to check

ReturnsAhead
+177.8% over a year, better than 7 of 7 peers.
Price tagPricier
P/E 70.9 vs industry 28.7.
GrowthStrong
Sales +23.6%, profit +33.7% a year over 3 years.
ProfitabilityAverage
ROCE 12.8% vs peer median 17.9%.
Balance sheetFair
Debt 0.18× equity, interest covered 6.2×, Piotroski 4 of 9.
Red flags1 to check
P/E of 70.9 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹2,141 Cr, #56 of 154 in its industry by size.

Defensive

Beta 0.45 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Mar 2026: sales ₹303 Cr · profit ₹43 Cr

Market cap: ₹2,141 Cr; Small cap
P/E: 70.9; Industry 28.7
Price to book: 6.27; Peers 4.99
Dividend yield: 0.00%
ROE: 13.2%; Peers 14.7%
ROCE: 12.8%; Peers 17.9%
Debt to equity: 0.18; Debt ₹62 Cr
EPS (TTM): ₹13.75; Face value ₹10
OPM (TTM): 27.4%; Net margin 14.2%
Sales growth: +41.5%; Latest quarter vs a year ago
Profit growth: +91.4%; Latest quarter vs a year ago
Price to sales: 7.07; EV/EBITDA 25.0

Strengths

Quarterly profit up 91.4% on a year ago.
Quarterly sales up 41.5% on a year ago.
Positive operating cash flow in each of the last 4 years.

Risks to check

P/E of 70.9 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Sakar Healthcare

Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company offers general and oncology products in various forms, such as liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. It also exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and…

Headquarters: Ahmedabad
Employees: 435
Sector: Healthcare
ISIN: INE732S01012
Website: sakarhealthcare.com

Price range

52 weeks

₹352.50₹1,229.85

Today

₹956.00₹1,018.95

Avg volume (3M): 1.6 L
1-year return: plus 177.8%
From 52-week high: minus 20.7%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
SAKARSakar Healthcare	975.55	minus 3.97%	2,141	70.9	6.27	12.8%	13.2%	27.4%	23.6%	33.7%	0.00%	plus 177.8%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore · latest reported Mar 26

SalesSelect a row below to chart it

Mar 25	Jun 25	Sep 25	Dec 25	Mar 26
50.2	52.7	57.6	70.3	71.1
34.5	40	46.2	51.7	44.9
15.7	12.7	11.4	18.6	26.2
31.3%	24.1%	19.7%	26.4%	36.9%
0.2	0.4	1.2	0.5	0.2
4.2	2.1	1.5	1.8	2.4
5.5	5.6	5.7	6.4	5.9
6.2	5.4	5.4	11	18.1
7.6%	13.3%	15.3%	6.4%	39.0%
5.8	4.7	4.5	10.2	11
2.65	2.11	2.03	4.59	4.96

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +23.6%
Profit CAGR 3Y: +33.7%
ROE: 13.2%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
133	153	178	252
–	+15.0%	+15.8%	+41.8%
99.3	114	127	181
34.1	39.2	50.2	70.2
25.6%	25.6%	28.3%	27.9%
3.4	1.2	0.1	0.8
5.5	6.7	7.9	7.7
15	18.1	20.9	23.6
−0.1	0.3	−0.1	–
16.9	15.9	21.5	39.8
24.4%	26.6%	18.7%	23.3%
12.8	11.7	17.5	30.5
–	minus 8.5%	+50.0%	+74.2%
6.86	5.67	8.00	–

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
19	21.7	21.9	22.2
154	241	264	302
119	79.4	86.4	70.5
43.8	47	43.4	86
336	389	415	481
280	315	322	333
13.5	2.5	17.3	13.8
3.5	0.5	0.3	0.3
39.2	70.5	76.1	134
336	389	415	481

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
33.3	24.5	34	49.3
−74.4	−51.5	−30.7	−28.4
41.1	27.4	−3.5	−21
0.1	0.4	−0.2	−0
−82.2	−59.6	−32.3	−28.4
−48.9	−35.1	1.7	20.9

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company.

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you